This Phase 1/2 clinical trial is investigating the safety and effectiveness of darovasertib (also known as IDE196) in people with advanced solid tumours, including metastatic uveal melanoma. Darovasertib is a targeted treatment designed to block a protein called PKC, which is abnormally activated in around 90% of uveal melanoma cases due to GNAQ or GNA11 genetic mutations. Researchers hope this may help slow tumour growth and improve outcomes for patients with metastatic disease.
The study is testing darovasertib both on its own and in combination with other targeted treatments, including crizotinib and binimetinib. Researchers are assessing the safest and most effective dose of these treatments, while also monitoring how well they control or shrink tumours. Participants receive regular scans, blood tests, and safety monitoring throughout the trial. Early results from the darovasertib and crizotinib combination have shown encouraging tumour response rates and progression-free survival in some patients with metastatic uveal melanoma.
Although this study has included sites in Europe and North America, there are currently no active UK locations listed for this specific trial (NCT03947385), and we are not currently aware of any plans for the study to open at UK sites.